Meet the Management Team
Our leadership team is responsible for the strategic direction and management of Liminal BioSciences. They are assisted in these responsibilities by our board and advisory members. Each member of the management team is responsible for a specific part of our business.
Bruce was appointed as Chief Executive Officer, effective 13 November 2020. Prior to that he was one of 2 Chief Operating Officers In this role he was responsible for the company’s discovery, clinical development, program management, CMC and business development functions related to Small Molecule Therapeutics.
An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than fourteen years’ experience with Liminal and has held a number of senior global positions across the organisation.
Prior to being appointed CEO he became COO in 2014, previously he was the Group CFO, a role he had held since 2008. Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance.
As well as being a chartered accountant, Bruce also brought to the role many years of experience in general management and operations. Prior to joining Liminal, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company.
Bruce is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Directors. He is also a Non-Executive Director and Chair of the Audit Committee of Porton Biopharma Limited, and is Deputy President of The Institute of Chartered Accountants of Scotland.
Bruce is based out of Liminal’s UK office in Cambridge.
Ms. Nicole Rusaw was appointed as Chief Financial Officer effective November 9, 2022. Prior to joining Liminal, Ms. Rusaw was the Chief Financial Officer of two publicly traded cannabis companies, Ionic Brands Corp. from June to December 2021, and Nabis Holdings Inc. from October 1, 2019 to January 27, 2021. Prior thereto, Ms. Rusaw acted as the Interim Chief Financial Officer of Nuvo Pharmaceuticals Inc. from August 2017 to September 2018 and Interim VP Operations and Administration from October 2018 to June 2019. Prior thereto, Ms. Rusaw was the Chief Financial Officer of Transition Therapeutics Inc. from December 2011 to October 2016.
Ms. Rusaw graduated from Brock University with First Class Honours Co-op and has obtained her Chartered Accountant professional designations, CPA, CA.
Marie is General Counsel & Secretary for the Liminal Group. As General Counsel Marie oversees the legal, compliance, intellectual property and corporate governance functions. Marie is also Corporate Secretary for Liminal.
Dr. Bridger has extensive experience in leading research and development through to commercialisation. Dr. Bridger previously served as Executive Vice President of Research and Development at Xenon Pharmaceuticals Inc., Senior Vice President of Research and Development of Genzyme Corporation and co-founded AnorMED Inc., eventually acquired by Genzyme.